YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Insider activity can provide investors with useful clues about how corporate leaders view their own companies. Executives and directors have firsthand knowledge of their businesses, making their disclosed stock transactions worth following…
Xenon Pharmaceuticals Inc. VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and c…
Xenon Pharmaceuticals' (XENE) safety data has raised investor concerns about a potential Food and Dr PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Ian Mortimer, President and Chief Executive Officer of Xenon Pharmaceuticals, as the recipient of the 2026 Bloom Burton Aw…
Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology t…
Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD). After 14 days, median reductions on the Adult AD…
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) advanced its epilepsy program while encountering a new obstacle to expansion. On September 17, it submitted a New Drug Application to the U.S. Food and Drug Administration for azetukalner in focal s…
Xenon Pharmaceuticals Inc. VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and c…
Shares of Steel Dynamics, Inc. (STLD) declined 4.1% after the company issued weaker third-quarter earnings guidance. Xenon Pharmaceuticals Inc.'s (XENE) shares plummeted 30.7% after the company announced that it is temporarily pausing enro…
Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment ©TIKR Key Stats for Xenon Pharmaceuticals Stock Price change for Xenon Pharmaceuticals stock: -31% $XENE Stock Price as of Sep. 19: $40 52-Week High: $73 $XENE…
Earlier this month, Xenon Pharmaceuticals submitted a New Drug Application to the US FDA for azetukalner in focal seizures, supported by two randomized, double-blind, placebo-controlled trials showing statistically significant seizure redu…
The S&P 500 Index ($SPX) (SPY) closed up by +0.17% on Friday, the Dow Jones Industrial Average ($DOWI) (DIA) closed down by -0.18%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.67%. December E-mini S&P futures (ESZ26) rose +0.20%, a…
Xenon Pharmaceuticals voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a 10-month low. Continue Reading
Medical Laboratory by Gorodenkoff via Shutterstock Xenon Pharmaceuticals (XENE) shares crashed on Friday after the biopharmaceutical firm said it has paused new patient enrollment in its clinical trials evaluating azetukalner. As investors…
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’ Continue Reading
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index decreasing 0.5% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[Red dollar sign pointing down with arrow, concept of financial loss, market decline and recession, 3d render] Xenon Pharmaceuticals (XENE [https://seekingalpha.com/symbol/XENE]) fell 30% to reach its lowest level since November after the…
Xenon Pharmaceuticals' (XENE) enrollment pause in an ongoing phase 3 trial of azetukalner adds risk PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Xenon Pharmaceuticals Inc.(NASDAQ:XENE) submitted a New Drug Application to the U.S. Food and Drug Administration for its investigational drug azetukalner to treat focal seizures. Simultaneously, the neuroscience-focused biopharmaceutical…
Xenon Pharmaceuticals XENE announced that it has submitted a new drug application (NDA) to the FDA for azetukalner, its lead investigational therapy for the treatment of focal onset seizures (FOS) in epilepsy. If approved, the company will…
The S&P 500 Index ($SPX) (SPY) is down by -0.03% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down by -0.23%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.20%. December E-mini S&P futures (ESZ26) are down -0.05%, and Decembe…
Xenon Pharmaceuticals voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a six-month low. Continue Reading
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’ Continue Reading
Investing.com - U.S. stock futures edged broadly higher on Friday, following a rally in stocks in the wake of the Federal Reserve's interest rate hike on Wednesday. Still guessing which names to buy? Our AI rebuilds its stock picks at the…
Check out the companies making the biggest moves premarket: Steel Dynamics , Nucor — Shares of both steel producers fell more than 1.5% after they delivered third-quarter earnings guidance that showed weaker-than-expected results compared…
(Updates with the latest share moves and details in the headline, first and second paragraph.) Xe PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news…
The Nasdaq Composite ended higher for the week, but not the Dow Jones Industrial Average or S&P 500. Credit: Michael Nagle / Bloomberg via Getty Images The Dow industrials and S&P 500 ended the week with losses, with the Nasdaq Composite t…
[Stock market activity shows price changes and trading movements in real time] FabrikaCr Stock futures edged up early Friday as easing oil prices and growing confidence in the Fed's inflation strategy extend Wall Street's post-decision ral…
Xenon Pharmaceuticals Inc. New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectively Enrollment in X-NOVA2 st…
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns. Continue Reading
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit. Continue Reading
On August 26, Xenon Pharmaceuticals (NASDAQ:XENE) announced that it will deliver six data presentations at the 16th European Epilepsy Congress in Athens, Greece, running September 5 through 9. The headline slot is an oral presentation of t…
Xenon Pharmaceuticals Inc. VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and c…
OTTAWA, Ontario, August 31, 2026--(BUSINESS WIRE)--BIOTECanada, the national industry association representing Canada's biotechnology sector, is pleased to announce the winners of the 2026 Gold Leaf Awards, recognizing outstanding leadersh…
Xenon Pharmaceuticals Inc. VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and c…
Xenon Pharmaceuticals recently announced that it presented multiple new data sets on its lead asset azetukalner at the 16th European Epilepsy Congress in Athens, including topline Phase 3 X‑TOLE2 results in focal onset seizures and long‑te…